Phase 1 Study of OTS167 in Patients With Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to test the safety and tolerability of an investigational drug called OTS167.OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in laboratory tests. It is being developed as an anti-cancer drug. In this first-in-human study OTS167 will be administered to patients with solid tumors which have not responded to treatment.
PhaseI, Single-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Preliminary Antineoplastic Activity of OTS167, a MELK Inhibitor, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male or female patients, >= 18 years of age at the time of obtaining informed consent.
Patients with a documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic.
Patients with a malignancy that is either refractory to standard therapy or for which no standard therapy is available.
Patients with a malignancy that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor.
Patients with measurable or non-measurable disease according to the response evaluation criteria in solid tumors (RECIST , v1.1)
Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
Patients, both male and female, who are either not of childbearing potential or who agree to use a medically effective method of contraception during the study and for 3 months after the last dose of study drug.
Patients with the ability to understand and give written informed consent for participation in this trial, including all evaluations and procedures as specified by this protocol.
Women who are pregnant or lactating. Women of child-bearing potential (WOCBP), and fertile men with a WOCBP-partner not using adequate birth control.
Patients with known central nervous system (CNS) or leptomeningeal metastases not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.
Patients with any hematologic malignancy. This includes leukemia (any form), lymphoma, and multiple myeloma.
Patients with any of the following hematologic abnormalities at baseline:
Absolute neutrophil count (ANC) < 1,500 per mm3
Platelet count < 100,000 per mm3
Patients with any of the following serum chemistry abnormalities at baseline:
Total bilirubin >= 1.5 × the ULN for the institution
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 3 × the upper limit normal (ULN) for the institution (>= 5 × if due to hepatic involvement by tumor)
Serum albumin < 2.5 g/dL
Creatinine >= 1.5 × ULN for the institution (or a calculated creatinine clearance < 60 mL/min/1.73 m2)
Patients with a significant cardiovascular disease or condition, including:
Congestive heart failure (CHF) currently requiring therapy
Need for antiarrhythmic medical therapy for a ventricular arrhythmia
History of congenital long QT syndrome or congenital short QT syndrome
Left ventricular ejection fraction < 50%
Uncontrolled hypertension (per the Investigator's discretion)
Class III or IV cardiovascular disease according to the New York Heart Association's (NYHA) Functional Criteria.
Myocardial infarction (MI) within 6 months prior to first study drug administration
Patients with a known or suspected hypersensitivity to any of the components of OTS167.
Patients with a known history of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
Patients with any other serious/active/uncontrolled infection, any infection requiring parenteral antibiotics, or unexplained fever > 38ºC within 1 week prior to first study drug administration.
Patients with inadequate recovery from acute toxicity associated with any prior antineoplastic therapy.
Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure within 4 weeks prior to first study drug administration.
Patients with any other life-threatening illness, significant organ system dysfunction, or clinically significant laboratory abnormality, which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluation of the safety of the study drug.
Patients with a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.
Patients with the inability or with foreseeable incapacity, in the opinion of the Investigator, to comply with the protocol requirements.